Company news
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A (SZSE:300294) news
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, Apr 25, 2026: China Resources Boya Bio-pharmaceutical Group: Q1…
View China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A →
Press releases & updates
China Resources Boya Bio-pharmaceutical Group: Q1 2026 saw steep declines in revenue and profit amid fierce competition and policy changes
April 24, 2026
China Resources Pharmaceutical Says CR Boya Bio-Pharmaceutical Posts Quarterly Unaudited Revenue RMB 321.1 Million, Net Profit RMB 30.0 Million
April 24, 2026
China Resources Boya Bio-pharmaceutical Group: Revenue up, profit down sharply on impairments and margin pressure; high dividend payout maintained
March 21, 2026
China Resources Pharmaceutical Logs FY Revenue RMB2.06 Bln For CR Boya Bio-Pharmaceutical
March 20, 2026
China Resources Pharmaceutical: Hui Ren Resigns As President Due To Job Change
February 26, 2026
China Resources Pharmaceutical Says 9M Net Profit For CR Boya Bio-Pharmaceutical At RMB343 Million
October 27, 2025
China Resources Boya Bio-pharmaceutical Group: Revenue up, profit down YTD, cash flow pressured, Boya Xinhe deconsolidated
October 25, 2025
China Resources Boya Bio-pharmaceutical Group: Revenue up 12.5% but net profit down 28.7% amid margin and policy pressures
August 22, 2025
China Resources Boya Bio-pharmaceutical Group: Revenue up 19.49% but net profit down 8.25% as costs rise and cash flow turns negative
April 24, 2025
China Resources Boya Bio-pharmaceutical Group: Net profit jumped 67% to ¥397M as core blood products outperformed despite revenue decline
March 18, 2025
China Resources Boya Bio-pharmaceutical Group: Revenue and profit fell on divestitures, but blood products and plasma supply expanded
October 24, 2024
China Resources Boya Bio-pharmaceutical Group: Net profit up 10.2% to RMB5.54 billion on 4.7% revenue growth; interim dividend declared
August 29, 2024
China Resources Boya Bio-pharmaceutical Group: Revenue down 41.87% year-over-year; net profit down 3.05%; major plasma acquisition completed
August 22, 2024